A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
Latest Information Update: 03 Nov 2024
At a glance
- Drugs XL 495 (Primary) ; Antineoplastics
- Indications Bladder cancer; Pelvic cancer; Renal cancer; Solid tumours; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Exelixis
- 14 Oct 2024 New trial record